• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Silo Pharma, Inc. - Common Stock (NQ:SILO)

0.4736 -0.0960 (-16.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,281,474
Open 0.5000
Bid (Size) 0.4450 (300)
Ask (Size) 0.4488 (200)
Prev. Close 0.5696
Today's Range 0.4012 - 0.5000
52wk Range 0.2210 - 1.190
Shares Outstanding 98,671,970
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top movers in Thursday's session ↗
Today 12:30 EDT
Via Chartmill
These stocks are gapping in today's session ↗
Today 10:30 EDT
Via Chartmill

Performance

YTD
+41.1%
+41.1%
1 Month
+36.2%
+36.2%
3 Month
+33.0%
+33.0%
6 Month
-12.5%
-12.5%
1 Year
-57.9%
-57.9%

More News

Read More
AINewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands Into AI With Qwikagents Asset Acquisition
Today 9:15 EDT
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
April 22, 2026
From Silo Pharma, Inc.
Via GlobeNewswire
What's going on in today's after hours session ↗
April 20, 2026
Via Chartmill
News headline image
Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics
April 20, 2026
From Silo Pharma, Inc.
Via GlobeNewswire
Wondering what's happening in today's after-hours session? ↗
April 07, 2026
Via Chartmill
Which stocks are most active on Tuesday? ↗
April 07, 2026
Via Chartmill
On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
April 07, 2026
Via Chartmill
Which stocks are moving on Tuesday? ↗
April 07, 2026
Via Chartmill
Gapping stocks in Tuesday's session ↗
April 07, 2026
Via Chartmill
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances IP Portfolio With EPO Notice of Intent to Grant Patent
April 07, 2026
Via Investor Brand Network
Topics Intellectual Property
These stocks that are showing activity before the opening bell on Tuesday. ↗
April 07, 2026
Via Chartmill
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
April 06, 2026
Via Chartmill
News headline image
Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy
April 06, 2026
From Silo Pharma, Inc.
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
April 03, 2026
Via Chartmill
MissionIRNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Authorizes $1 Million Share Repurchase Program
February 24, 2026
Via Investor Brand Network
Which stocks are moving before the opening bell on Tuesday? ↗
February 24, 2026
Via Chartmill
What's going on in today's after hours session ↗
February 23, 2026
Via Chartmill
News headline image
Silo Pharma Announces Share Buyback Program
February 23, 2026
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Receives Japan Patent Allowance for SPC-15 PTSD Candidate10
February 18, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio
February 18, 2026
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15
December 30, 2025
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD
November 17, 2025
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Selects Alphaledger’s T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain
October 29, 2025
From Silo Pharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Silo Pharma, Inc. - Common Stock publicly traded?
Yes, Silo Pharma, Inc. - Common Stock is publicly traded.
What exchange does Silo Pharma, Inc. - Common Stock trade on?
Silo Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Silo Pharma, Inc. - Common Stock?
The ticker symbol for Silo Pharma, Inc. - Common Stock is SILO on the Nasdaq Stock Market
What is the current price of Silo Pharma, Inc. - Common Stock?
The current price of Silo Pharma, Inc. - Common Stock is 0.4736
When was Silo Pharma, Inc. - Common Stock last traded?
The last trade of Silo Pharma, Inc. - Common Stock was at 04/23/26 04:00 PM ET
What is the market capitalization of Silo Pharma, Inc. - Common Stock?
The market capitalization of Silo Pharma, Inc. - Common Stock is 46.73M
How many shares of Silo Pharma, Inc. - Common Stock are outstanding?
Silo Pharma, Inc. - Common Stock has 47M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap